aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07, Bloomberg Earnings reports.
Shares of aTyr Pharma (LIFE) traded up $0.05 during mid-day trading on Wednesday, reaching $3.70. The company had a trading volume of 18,700 shares, compared to its average volume of 106,687. The company has a quick ratio of 6.13, a current ratio of 6.13 and a debt-to-equity ratio of 0.29. aTyr Pharma has a one year low of $2.10 and a one year high of $6.50.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2017/11/15/atyr-pharma-inc-life-posts-earnings-results-beats-expectations-by-0-07-eps.html.
A number of analysts have recently weighed in on LIFE shares. ValuEngine cut aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating and set a $5.25 price objective for the company. in a research report on Thursday, September 28th. Piper Jaffray Companies started coverage on aTyr Pharma in a research report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price objective for the company. Finally, BMO Capital Markets set a $4.00 price objective on aTyr Pharma and gave the stock a “hold” rating in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.62.
In other news, CEO John Mendlein bought 37,736 shares of aTyr Pharma stock in a transaction that occurred on Thursday, August 31st. The stock was bought at an average price of $2.65 per share, for a total transaction of $100,000.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul Schimmel bought 94,336 shares of aTyr Pharma stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, with a total value of $249,990.40. Following the purchase, the director now directly owns 40,440 shares in the company, valued at $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.